Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

457.36 -5.77 (-1.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
68 69 Next >
News headline image
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy? ↗
Via The Motley Fool
News headline image
What You Missed On Friday ↗
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? ↗
Via The Motley Fool
News headline image
Small- To Mid-Cap Biotech Trades Poised For Gains ↗
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these... 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (21 Ratings) ↗
 
Via Benzinga
News headline image
Is Vertex Pharmaceuticals Stock a Buy in 2025? ↗
Via The Motley Fool
News headline image
How Is The Market Feeling About Vertex Pharmaceuticals? ↗
 
Via Benzinga
News headline image
FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief ↗
FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide patients with more options. 
Via Benzinga
Topics Cannabis
News headline image
What's going on in today's session: S&P500 movers ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
News headline image
Top S&P500 movers in Friday's session ↗
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Vertex Pharmaceuticals Stock Soars As Non-Opioid Pain Treatment Gets FDA Nod ↗
Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing acute pain. 
Via Talk Markets
Topics Stocks / Equities
News headline image
How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter ↗
The company won Food and Drug Administration approval for its non-opioid painkiller pill on Thursday. 
Via Investor's Business Daily
News headline image
Vertex Pharmaceuticals Shares Are Up Today: What's Going On? ↗
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen its position in both pain management and gene therapy. 
Via Benzinga
News headline image
Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical, AbbVie And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Friday's pre-market session: top gainers and losers in the S&P500 index ↗
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
News headline image
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
From Vertex Pharmaceuticals
Via Business Wire
News headline image
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller ↗
The first-in-class drug had suffered a setback in December. 
Via Investor's Business Daily
News headline image
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
This Everest Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever. ↗
Via The Motley Fool
News headline image
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher ↗
Via The Motley Fool
News headline image
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy. 
Via MarketBeat
News headline image
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever ↗
Via The Motley Fool
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
3 Unstoppable Stocks to Buy in 2025 ↗
Via The Motley Fool
News headline image
HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws' ↗
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its gene-editing therapy for sickle cell disease. 
Via Benzinga
News headline image
Vertex's Pain Drug: Big Pharma's Next Major Success?
Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market. 
Via MarketBeat
News headline image
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30? ↗
Via The Motley Fool
News headline image
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.